Logo image of QTRX

QUANTERIX CORP (QTRX) Stock Fundamental Analysis

NASDAQ:QTRX - Nasdaq - US74766Q1013 - Common Stock - Currency: USD

4.79  +0.29 (+6.44%)

Premarket: 4.79 0 (0%)

Fundamental Rating

3

Taking everything into account, QTRX scores 3 out of 10 in our fundamental rating. QTRX was compared to 56 industry peers in the Life Sciences Tools & Services industry. QTRX has a great financial health rating, but its profitability evaluates not so good. QTRX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year QTRX has reported negative net income.
QTRX had a negative operating cash flow in the past year.
QTRX had negative earnings in each of the past 5 years.
QTRX had a negative operating cash flow in each of the past 5 years.
QTRX Yearly Net Income VS EBIT VS OCF VS FCFQTRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of QTRX (-12.22%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -15.06%, QTRX is in the better half of the industry, outperforming 60.71% of the companies in the same industry.
Industry RankSector Rank
ROA -12.22%
ROE -15.06%
ROIC N/A
ROA(3y)-12.78%
ROA(5y)-12.3%
ROE(3y)-15.57%
ROE(5y)-15.02%
ROIC(3y)N/A
ROIC(5y)N/A
QTRX Yearly ROA, ROE, ROICQTRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K

1.3 Margins

QTRX's Gross Margin of 59.98% is amongst the best of the industry. QTRX outperforms 82.14% of its industry peers.
QTRX's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for QTRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.73%
GM growth 5Y5.05%
QTRX Yearly Profit, Operating, Gross MarginsQTRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

7

2. Health

2.1 Basic Checks

QTRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for QTRX has been increased compared to 1 year ago.
Compared to 5 years ago, QTRX has more shares outstanding
There is no outstanding debt for QTRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
QTRX Yearly Shares OutstandingQTRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
QTRX Yearly Total Debt VS Total AssetsQTRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

QTRX has an Altman-Z score of 0.66. This is a bad value and indicates that QTRX is not financially healthy and even has some risk of bankruptcy.
QTRX's Altman-Z score of 0.66 is on the low side compared to the rest of the industry. QTRX is outperformed by 67.86% of its industry peers.
There is no outstanding debt for QTRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.66
ROIC/WACCN/A
WACC10.52%
QTRX Yearly LT Debt VS Equity VS FCFQTRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

QTRX has a Current Ratio of 8.66. This indicates that QTRX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 8.66, QTRX belongs to the best of the industry, outperforming 91.07% of the companies in the same industry.
QTRX has a Quick Ratio of 7.88. This indicates that QTRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.88, QTRX belongs to the top of the industry, outperforming 91.07% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.66
Quick Ratio 7.88
QTRX Yearly Current Assets VS Current LiabilitesQTRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

QTRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -23.96%.
The Revenue has grown by 12.30% in the past year. This is quite good.
The Revenue has been growing by 19.37% on average over the past years. This is quite good.
EPS 1Y (TTM)-23.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.54%
Revenue 1Y (TTM)12.3%
Revenue growth 3Y7.51%
Revenue growth 5Y19.37%
Sales Q2Q%-5.4%

3.2 Future

The Earnings Per Share is expected to grow by 0.97% on average over the next years.
QTRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.03% yearly.
EPS Next Y-29.07%
EPS Next 2Y-1.19%
EPS Next 3Y8.87%
EPS Next 5Y0.97%
Revenue Next Year-2.73%
Revenue Next 2Y5.65%
Revenue Next 3Y7.37%
Revenue Next 5Y16.03%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
QTRX Yearly Revenue VS EstimatesQTRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
QTRX Yearly EPS VS EstimatesQTRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for QTRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QTRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QTRX Price Earnings VS Forward Price EarningsQTRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QTRX Per share dataQTRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.19%
EPS Next 3Y8.87%

More info and screens

0

5. Dividend

5.1 Amount

QTRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

QUANTERIX CORP

NASDAQ:QTRX (5/16/2025, 8:16:17 PM)

Premarket: 4.79 0 (0%)

4.79

+0.29 (+6.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners96.04%
Inst Owner Change1.64%
Ins Owners6.92%
Ins Owner Change2.25%
Market Cap185.95M
Analysts81.82
Price Target12.33 (157.41%)
Short Float %7.87%
Short Ratio3.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.69%
Min EPS beat(2)-15.34%
Max EPS beat(2)11.96%
EPS beat(4)3
Avg EPS beat(4)5.95%
Min EPS beat(4)-15.34%
Max EPS beat(4)19.08%
EPS beat(8)6
Avg EPS beat(8)22.98%
EPS beat(12)7
Avg EPS beat(12)3.57%
EPS beat(16)10
Avg EPS beat(16)3.72%
Revenue beat(2)2
Avg Revenue beat(2)1.42%
Min Revenue beat(2)0.1%
Max Revenue beat(2)2.75%
Revenue beat(4)3
Avg Revenue beat(4)0.57%
Min Revenue beat(4)-0.58%
Max Revenue beat(4)2.75%
Revenue beat(8)7
Avg Revenue beat(8)5.57%
Revenue beat(12)9
Avg Revenue beat(12)2.4%
Revenue beat(16)13
Avg Revenue beat(16)4.72%
PT rev (1m)-11.59%
PT rev (3m)-32.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-59.76%
EPS NY rev (1m)-2.22%
EPS NY rev (3m)-43.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20.5%
Revenue NY rev (1m)-6.2%
Revenue NY rev (3m)-15.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.1
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.57
EV/EBITDA N/A
EPS(TTM)-1.19
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS4.37
BVpS8.5
TBVpS8.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.22%
ROE -15.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.98%
FCFM N/A
ROA(3y)-12.78%
ROA(5y)-12.3%
ROE(3y)-15.57%
ROE(5y)-15.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.73%
GM growth 5Y5.05%
F-Score4
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 52.11%
Cap/Sales 1.99%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.66
Quick Ratio 7.88
Altman-Z 0.66
F-Score4
WACC10.52%
ROIC/WACCN/A
Cap/Depr(3y)110.86%
Cap/Depr(5y)140.92%
Cap/Sales(3y)5.57%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-23.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.54%
EPS Next Y-29.07%
EPS Next 2Y-1.19%
EPS Next 3Y8.87%
EPS Next 5Y0.97%
Revenue 1Y (TTM)12.3%
Revenue growth 3Y7.51%
Revenue growth 5Y19.37%
Sales Q2Q%-5.4%
Revenue Next Year-2.73%
Revenue Next 2Y5.65%
Revenue Next 3Y7.37%
Revenue Next 5Y16.03%
EBIT growth 1Y-40.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.58%
EBIT Next 3Y14.8%
EBIT Next 5YN/A
FCF growth 1Y-69.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-86.56%
OCF growth 3YN/A
OCF growth 5YN/A